Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy’s and Cipla saw significant drops in their net profits and operating margins. However, their domestic businesses continued to perform well, offering a positive outlook. Obesity therapies and specialty product launches are expected to drive future growth for these companies. Analysts have consequently reduced earnings forecasts for the upcoming fiscal years.
Warren Buffett sounds alarm as stock market warning returns for only second time in 155 years
Warren Buffett’s caution comes as the S&P 500’s CAPE ratio approaches levels seen only during periods of extreme valuations. While elevated readings can signal weaker
September 19, 2026